Results 181 to 190 of about 297,519 (217)
Some of the next articles are maybe not open access.
Nihon rinsho. Japanese journal of clinical medicine, 2008
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
Dengue is the most important mosquito borne virus infection in the tropics. Based on the effects of global warming, it is expected that dengue epidemic areas will further expand in the next decades unless effective and affordable vaccines are made available soon.
Scott B. Halstead, David W. Vaughn
openaire +3 more sources
Dengue vaccines: implications for dengue control
Current Opinion in Infectious Diseases, 2017Purpose of review Dengue, the most common arbovirus, is an increasingly significant cause of morbidity worldwide. After decades of research, an approved tetravalent dengue vaccine is finally available. Models constructed using recently available vaccine efficacy data allow for a data-driven discussion of the potential impact of
Matthew L, Robinson, Anna P, Durbin
openaire +2 more sources
Vaccine, 2017
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources
The vaccine against Dengue virus (DENV), Dengvaxia® (CYD), produced by Sanofi-Pasteur, has been registered by several national regulatory agencies; nevertheless, the performance and security of this vaccine have been challenged in a series of recent papers.
Ruth Aralí, Martínez-Vega +3 more
openaire +2 more sources
The Lancet, 2002
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Every year there are several hundred thousand acres of dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS) resulting in thousands of deaths. The only method currently available to prevent dengue infections is the control of Aedes aegypti the mosquito vector. This approach has proved expensive and mostly unworkable.
Scott B, Halstead, Jacqueline, Deen
openaire +2 more sources
Dengue infection and advances in dengue vaccines for children
The Lancet Child & Adolescent Health, 2019Dengue viruses are endemic in most tropical and subtropical countries where they produce disease ranging from a mild fever to a severe, potentially fatal vascular permeability syndrome. We reviewed the status of development and testing in children of three vaccines designed to protect against the four dengue viruses.
Scott B, Halstead, Leonila F, Dans
openaire +2 more sources
Introducing dengue vaccine: Implications for diagnosis in dengue vaccinated subjects
Vaccine, 2016Diagnosis of dengue virus infections is complicated by preference for different diagnostic tests in different post onset days of illness and the presence of multiple serotypes leading to secondary and tertiary infections. The sensitivity of the most commonly employed diagnostic assays such as anti dengue IgM capture (MAC) ELISA and non structural ...
openaire +2 more sources
Advancing dengue vaccine development
Science, 2017Insights into the natural history of dengue virus infection guide vaccine ...
Mark B, Feinberg, Rafi, Ahmed
openaire +2 more sources
Advances in dengue vaccine development
Human Vaccines, 2009Dengue viruses are the most important arboviruses causing human disease. Expansion of the disease in recent decades to include more geographical areas of the world, an appreciation of the disease burden and market potentials have spurred a flurry of activity in the development of vaccines to combat dengue viruses.
Kanakatte, Raviprakash +3 more
openaire +2 more sources
This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design.
openaire +2 more sources
openaire +2 more sources
Current issues in dengue vaccination
Current Opinion in Infectious Diseases, 2013Dengue is a global health problem and of concern to travelers and deploying military personnel, with development and licensure of an effective tetravalent dengue vaccine a public health priority. The recent performance of the lead dengue vaccine in a phase 2b efficacy trial underscores dengue vaccine development challenges.
Stephen J, Thomas, Timothy P, Endy
openaire +2 more sources